3.4 million deaths averted through GAVI-funded immunisation programmes
GENEVA, 29 October 2008 - 3.4 million deaths will be averted in the world's poorest countries through immunisation funded by the GAVI Alliance between 2000 and 2008, according to new data released by the World Health Organization (WHO).
WHO monitors the projected impact of GAVI programmes in 76 developing countries. The new projections show an increase of 600,000 deaths to be averted in the future compared to the period 2000-2007. The data will be presented to the GAVI Alliance Board on Wednesday in Geneva.
"Our front-loaded effort at scaling up immunisation programmes works well, preventing millions of premature deaths and much debilitating illness, as well as ensuring immunisation's place as a global health priority as we drive towards the Millennium Development Goals (MDGs)," said Dr Julian Lob-Levyt, Executive Secretary of the GAVI Alliance.
WHO also projects that, by the end of 2008, a cumulative 213 million children will have been reached with GAVI-supported vaccines.
The cumulative number of children benefitting from three doses of Hib vaccine (Haemophilus influenzae type B) is projected to rise to 41.7 million by the end of 2008, up from an estimated 28.2 million just 12 months earlier. The Hib bacterium can cause severe infections such as meningitis and pneumonia.
Hepatitis B vaccine is projected to have reached a cumulative 192.2 million children by end 2008, up from an estimated 155.7 million at the end of 2007. With 2.5 million deaths averted through vaccination against Hepatitis B alone, this is GAVI's single biggest success story.
DTP3 coverage and yellow fever vaccine are also showing continued increases. DTP3 (three doses of diphtheria, tetanus, and pertussis) is the accepted indicator of basic immunisation coverage in developing countries. The number of deaths averted only refers to the impact of vaccination against pertussis, hepatitis B and haemophilus influenzae type B.
"As financial markets tumble, these numbers show the positive results of investment in human lives," Julian Lob-Levyt said. "Donors and donor governments can take this as encouragement to continue funding health interventions driven by the developing countries themselves. Only through long term predictable funding can we guarantee that poor countries are able to improve their immunisation programmes in order to saves lives."
Of the 9.2 million children who die before reaching their fifth birthday every year, close to one quarter die from diseases that could be prevented with currently available or new vaccines.
On Thursday 30 October 2008, the GAVI Alliance Board will discuss a New Vaccine Investment Strategy that will offer poor countries more vaccines to alleviate their disease burden. This will have direct implications for GAVI's funding needs.
About the GAVI Alliance
The GAVI Alliance is a public-private partnership of major stakeholders in vaccines and immunisation. It includes developing country and donor governments, WHO, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, NGOs, the Bill & Melinda Gates Foundation and other private philanthropists. For the period 2000-2015, GAVI has so far committed US$3.7 billion in multi-year grants to the world's poorest countries. The GAVI Alliance is funded by The Bill & Melinda Gates Foundation, the European Commission, and governments including Australia, Canada, Denmark, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, South Africa, Spain, Sweden, the United Kingdom and the United States.
For more information, please contact:
+41 22 909 7165 office
+ 41 79 240 45 59 mobile
+41 22 909 6524 office
+41 79 251 8581 mobile
Photo and video requests:
Sandra Scolari +41 22 909 6528